Therefore, further investigation for the new aptamers that would disrupt and/or abrogate SRC-3 activity and designing new nanocarrier systems that will effectively deliver these aptamers into CSCs and tumor cells will be important to inhibit/overcome SRC-3-promoted malignant behaviors in BCa. The gene discussed is NCOA3; the disease is neoplasm.